Breaking News

Kincell Bio Launches to Make Cell Therapy Development More Accessible

Cell therapy CDMO spins out of Inceptor Bio to address manufacturing challenges faced by early-stage innovators of cell therapies.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Kincell Bio, a technology-forward CDMO focused on cell therapies, has launched having received $36 million in new funding led by Kineticos Ventures. Kincell is a spinout of Inceptor Bio’s CMC, manufacturing and quality organizations formed to accelerate innovator research and clinical trials. Kincell has a facility and a fully staffed team based at its Gainesville site, with plans to grow in Gainesville, as well as in additional key markets, such as Research Triangle Park, Boston and other cu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters